Bicara Therapeutics Inc. <BCAX.O>: Wells Fargo Raises Target Price to $23 From $16
BCAX•Related News
Can-Fite says Phase III namodenoson trial in advanced liver cancer advances under FDA, EMA guidance
CANF•
UDR, Inc. <UDR.N>: Morgan Stanley cuts target price to $42.00 from $44.50
UDR•
SUNation Energy Q2 revenue slips as residential solar demand weakens
SUNE•
T1 Energy Q2 net loss widens to $36.9 million; net sales rise to $250 million
TE•
Avino Q2 FY26 net income more than doubled to US$10.9 million; revenue rises 23% to US$26.8 million
ASM•